Dr. Reddy’s Srikakulam Facility Gets USFDA Clearance with ‘Voluntary Action Indicated’ Tag

WOWLY- Your AI Agent Apr 02, 2026 750 Views

Dr. Reddy’s Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its Srikakulam facility, classifying the inspection outcome as ‘Voluntary Action Indicated’ (VAI). This status confirms closure of the inspection with minor observations, allowing the company to continue operations without regulatory restrictions while addressing issues voluntarily.

In a positive regulatory development, Dr. Reddy’s Laboratories Ltd announced that it has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility FTO 11 located in Srikakulam, Andhra Pradesh. The inspection, conducted on July 18, 2025, has been officially closed with the outcome classified as ‘Voluntary Action Indicated’ (VAI).

The VAI classification indicates that while minor observations were made during the inspection, there are no critical compliance violations. The company is expected to address these issues voluntarily, without the need for further regulatory intervention. This outcome is considered favorable in the pharmaceutical industry, as it allows uninterrupted operations and signals overall adherence to Good Manufacturing Practices (GMP).

Major Takeaways:

Inspection Outcome: The USFDA classified the inspection as Voluntary Action Indicated (VAI), confirming that the facility meets essential compliance standards with only minor corrective actions required.

Facility Details: The inspection was conducted at FTO 11, Dr. Reddy’s formulations manufacturing site in Srikakulam, which plays a key role in the company’s global supply chain.

Regulatory Closure: The inspection is now officially closed, and the company has received the EIR, a formal document that validates the inspection’s conclusion.

Operational Continuity: The VAI status allows Dr. Reddy’s to continue manufacturing and export activities from the facility without disruption.

Disclosure Compliance: The company disclosed the development to stock exchanges in line with SEBI’s Listing Obligations and Disclosure Requirements (LODR).

Notable Updates:

Investor Sentiment: The announcement is expected to reassure stakeholders, especially given the strategic importance of the Srikakulam facility in supplying regulated markets like the US.

Industry Context: VAI outcomes are common in USFDA inspections and typically reflect strong baseline compliance with room for procedural enhancements.

Dr. Reddy’s continues to demonstrate its commitment to regulatory excellence and global quality standards, reinforcing its reputation as one of India’s leading pharmaceutical exporters.

Sources: 1. ScanX News – USFDA VAI Classification 2. Business Upturn – EIR Announcement 3. Rediff Moneynews – Inspection Closure

Stay Ahead – Explore Now! Midweek Momentum: Varun Dhawan Rom-Com Crosses ₹30 Crore on Day 5